Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T2PL
|
|||
| Former ID |
DIB006677
|
|||
| Drug Name |
Calcitriol
|
|||
| Synonyms |
calcitriol; Rocaltrol; 32222-06-3; Calcijex; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; Soltriol; 1alpha,25-Dihydroxycholecalciferol; Calcitriolum; Dihydroxyvitamin D3; 1,25-DHCC; 1,25-Dihydroxyvitamin D; Vectical; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxyvitamin D3; Calcitriolum [INN-Latin]; UNII-FXC9231JVH; 1alpha,25(OH)2D3; DN-101; 1,25-Dihydroxycholecaliferol; CCRIS 5522; Ro 21-5535; HSDB 3482; 1-alpha,25-Dihydroxycholecalciferol; EINECS 250-963-8; DN 101; Calcitriol (chemotherapy-induced alopecia); Calcitriol (chemotherapy-induced alopecia), Cytotech Labs; Calcitriol (API-31543, drug-induced alopecia), Cytotech Labs; 1alpha,25 dihydroxyvitamin D(3)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Congenital alopecia [ICD-11: LC30; ICD-10: Q84.0] | Approved | [1], [2] | |
| Company |
Cytotech Labs LLC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H44O3
|
|||
| Canonical SMILES |
CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
|
|||
| InChI |
1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1
|
|||
| InChIKey |
GMRQFYUYWCNGIN-NKMMMXOESA-N
|
|||
| CAS Number |
CAS 32222-06-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4817, 596357, 628349, 646010, 3225659, 7847197, 7850823, 7978847, 8143990, 8616278, 11528639, 12012574, 14758022, 14855739, 24850808, 24893473, 26719902, 26754891, 26759742, 39289574, 46386784, 46391717, 46508162, 47588739, 47662005, 47959455, 48334202, 48415682, 49681438, 49681793, 50110818, 53789169, 53789350, 56311224, 56311227, 56311279, 56311508, 56311775, 56312928, 56313898, 56314589, 56365636, 57288572, 57357744, 57647688, 71824963, 80321599, 89088644, 92308336, 92308939
|
|||
| ChEBI ID |
CHEBI:17823
|
|||
| ADReCS Drug ID | BADD_D00337 | |||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Pasteurellales | ||||
|
Studied Microbe: Haemophilus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Haemophilus was decreased by Calcitriol (p < 0.001). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
|
Studied Microbe: Megasphaera
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Megasphaera was increased by Calcitriol (p < 0.001). | |||
|
Studied Microbe: Veillonella
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Veillonella was decreased by Calcitriol (p < 0.001). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vitamin D3 receptor (VDR) | Target Info | Agonist | [4] |
| KEGG Pathway | Endocrine and other factor-regulated calcium reabsorption | |||
| Mineral absorption | ||||
| Tuberculosis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Vitamin D metabolism and pathway | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
| Direct p53 effectors | ||||
| RXR and RAR heterodimerization with other nuclear receptor | ||||
| Retinoic acid receptors-mediated signaling | ||||
| Validated transcriptional targets of deltaNp63 isoforms | ||||
| Validated transcriptional targets of TAp63 isoforms | ||||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Ovarian Infertility Genes | |||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Vitamin D Receptor Pathway | ||||
| Drug Induction of Bile Acid Pathway | ||||
| Nuclear Receptors | ||||
| Vitamin D Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2779). | |||
| REF 2 | ClinicalTrials.gov (NCT02186665) Plaque Psoriasis Study in Pediatric Subjects. U.S. National Institutes of Health. | |||
| REF 3 | Gut microbiota interactions with the immunomodulatory role of vitamin D in normal individuals. Metabolism. 2017 Apr;69:76-86. | |||
| REF 4 | Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.